ITOS vs. SDGR, EVO, OCUL, VERA, ETNB, BHVN, ANIP, MESO, EWTX, and JANX
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Schrodinger (SDGR), Evotec (EVO), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), 89BIO (ETNB), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs. Its Competitors
iTeos Therapeutics (NASDAQ:ITOS) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.
iTeos Therapeutics presently has a consensus target price of $15.86, suggesting a potential upside of 57.47%. Schrodinger has a consensus target price of $33.25, suggesting a potential upside of 61.17%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts plainly believe Schrodinger is more favorable than iTeos Therapeutics.
iTeos Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
In the previous week, Schrodinger had 6 more articles in the media than iTeos Therapeutics. MarketBeat recorded 9 mentions for Schrodinger and 3 mentions for iTeos Therapeutics. Schrodinger's average media sentiment score of 0.39 beat iTeos Therapeutics' score of 0.34 indicating that Schrodinger is being referred to more favorably in the news media.
iTeos Therapeutics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
iTeos Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -83.39%. iTeos Therapeutics' return on equity of -21.37% beat Schrodinger's return on equity.
Summary
iTeos Therapeutics and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 7/7/2025 by MarketBeat.com Staff
Free ITOS Stock Alerts